Recently n-3 polyunsaturated fatty acids (PUFAs) have been reported to play protective roles against cardiovascular diseases. Pulmonary thromboembolism (PTE) is one of the critical diseases in the circulatory system. However the relationship between n-3 PUFAs and PTE has not been reported. A total of 144 outpatients of the division of cardiology, including 12 of PTE cases, were enrolled in the present study and serum levels of eicosapentaenoic acid (EPA) and arachidonic acid (AA) were analyzed. We found that the EPA/AA ratio of the patients with PTE (the PTE group) was significantly lower than that of the patients without PTE (the non-PTE group) (p50.007 for log EPA/log AA ratio). Next, the PTE group was divided into two groups by the presence or absence of malignant carcinoma. The PTE without carcinoma group showed significantly lower EPA/AA ratio than that of the non-PTE group (p50.002 for log EPA/log AA ratio). However, the PTE with carcinoma group did not show the statistical difference in EPA/AA ratio compared with the non-PTE group (p50.39). These data indicate that PTE may be associated with a low EPA/AA ratio, although the presence of malignant carcinoma should be taken into account.
J Nutr Sci Vitaminol, 59, [474] [475] [476] [477] 2013 Accumulating studies have shown that n-3 polyunsaturated fatty acids (PUFAs) have protective properties against cardiovascular diseases (CVD) (1-3). A study has indicated that high intake of n-3 PUFAs is one possible reason for the relatively low prevalence of CVD in Japan (4); however, it was reported that the relative ratio of n-3 PUFA intake in Japan was decreasing (5).
Pulmonary thromboembolism (PTE) is one of the critical circulatory diseases, in which the thrombi usually originate in the deep veins of the lower limbs. The incidence of PTE in Japan was relatively low in the past, but it is increasing as a westernized lifestyle replaces the traditional one.
These data may suggest a link of n-3 PUFAs with PTE. However there have been no clinical studies concerning the relationship between n-3 PUFAs and PTE, which led us to study serum fatty acid composition in relation to PTE prevalence.
Materials and Methods
From July 2011 to October 2011, among the outpatients who visited the Division of Cardiology in our hospital, a total of 144 patients who received blood sampling tests for serum fatty acid composition were enrolled in the present study. The present study was approved by the ethical committee in Kinki Central Hospital and carried out in accordance with the code of ethics of the World Medical Association (Declaration of Helsinki).
All patients underwent blood sampling after more than an 8-h fasting period in the morning. Serum fatty acid composition was determined by the gas-chromatography method performed by SRL Inc, Tokyo, Japan. For the statistical analyses, the data for the fatty acid composition were log-transformed to be in the normal distribution.
The diagnosis of PTE was done by the detection of pulmonary arterial thrombi by chest contrast enhanced computed tomography (CE-CT). Outpatients who did not have any echocardiographic signs of pulmonary hypertension, clinical history of PTE or clinical signs for PTE did not undergo the chest CE-CT examination because they were unlikely to have PTE. The PTE patients were reported negative for coagulation disorders, including anti-phospholipid syndrome, protein C deficiency, protein S deficiency and antithrombin 3 deficiency.
Data 
Results and Discussion
All participants' characteristics are shown in Table  1 . Male patients were twice as many as female ones. Twelve (8.3%) patients had PTE in this cohort. We compared the background characteristics between the patients without PTE (non-PTE) and those with PTE (Table 2 ). There are no differences in age, body mass index or blood pressure. In the PTE group, half of the patients had carcinoma (p,0.0001 as compared with non-PTE group).
As shown in the biochemical analyses (Table 3) , the EPA value and EPA/AA ratio of the PTE group were lower than those of non-PTE group (p50.017 for log EPA and 0.007 for log EPA/log AA ratio).
As for the age and the EPA/AA ratio, the present cohort is comparable to that of the recent report on patients with coronary artery diseases (6). The contemporary data on fatty acid composition of the general population are not sufficient for discussion. In the Kumihama study, the EPA/AA ratio was reported as about 0.6, where the blood sampling was carried out from 1994 to 1996 (7), indicating that the data are not up to date. Recently we reported that the EPA/AA ratio of the general population was 0.33, for blood sampling which was performed in 2011 (8). However, it seems to be difficult to directly compare this data with that of the present study because the participants of the general population study were younger than those of the present study. Considering background differences among previous studies, the EPA/AA ratio of the present cohort does not seem to be at an extremely abnormal level.
Comparing with the non-PTE group, the PTE group had slightly but not significantly higher levels in body mass index, triglyceride and HbA1c, and a significantly lower value in HDL-cholesterol. These data indicate that the PTE group, as a whole, might have more features of metabolic syndrome than the non-PTE group. These differences might result in the lower EPA/AA ratio in the PTE group.
So far, some reports have demonstrated that n-3 PUFAs inhibit platelet aggregation (9-11) and reduce the generation of chemical mediators which activate platelet functions (9, 12) . Notably, a recent study revealed that anti-platelet therapy prevented the recurrence of venous thrombosis (13) . Thus, we would like to propose that a low EPA/AA ratio might be one of the underlying conditions to raise platelet activities and that the anti-platelet effect of EPA could have preventive actions against venous thrombosis and PTE. A recent report, which showed that administration of EPA prevented venous thromboembolism in a rat model (14) , further supports our proposal.
Since the presence of carcinoma is one of the risk factors of PTE, we divided the PTE group into two groups by the presence (n56) or absence (n56) of malignant carcinoma. Values of EPA and the EPA/AA ratio of the PTE without carcinoma group were 33.6 mg/L and 0.151 (Table 4) . Multiple comparisons for log EPA and log EPA/log AA ratio among groups of non-PTE, PTE without carcinoma and PTE with carcinoma revealed that the PTE without carcinoma group had a significantly lower log EPA level (p50.009) and log EPA/ log AA ratio (p50.002) than the non-PTE group (Table  4) . On the other hand, the PTE with carcinoma group did not show differences in log EPA or log EPA/log AA ratio as compared with the non-PTE group (p50.40 for log EPA and p50.39 for log EPA/log AA ratio) (Table 4) .
In clinical practice, patients with carcinoma are not uniform. They can show a wide spectrum of nutritional status from obesity to cachexia, depending upon the disease stage and the origin of the carcinoma. It is wellrecognized that the intake of n-3 PUFAs determines the level of EPA (15) . Although the fatty acid composition in malignancy has not been fully elucidated, it is expected to vary widely. Indeed, it seems that some patients with carcinoma had low EPA/AA ratios, and others did not. This phenomenon might have resulted in the failure to show a significant difference in EPA/AA ratio between the groups of PTE with and without carcinoma.
Under these conditions, it is not uncommon that deep vein thrombosis/PTE are associated with cancer. This is known as Trousseau syndrome (16). Secreted factors produced by carcinoma are considered to initiate blood coagulation in this disorder (17) . We speculate that the coagulatory disorders caused by carcinoma might affect the formation of venous thrombus, irrespective of the EPA/AA ratio. As a result, the EPA/AA ratio in the PTE with carcinoma group might remain statistically comparable to that of the non-PTE group.
There are some limitations to this study. Our study is a single center cross-sectional study and includes a small sample size, indicating the difficulties in deriving definitive evidence. Further clinically interventional studies or biological research is necessary to confirm the findings.
In conclusion, we found that patients with PTE have low serum EPA/AA ratios, although the presence of malignant carcinoma should be taken into account. 1978. Eicosapentaenoic acid and prevention of throm- 
